451 related articles for article (PubMed ID: 9624531)
1. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
2. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF
Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537
[TBL] [Abstract][Full Text] [Related]
3. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.
Maitra A; Wistuba II; Washington C; Virmani AK; Ashfaq R; Milchgrub S; Gazdar AF; Minna JD
Am J Pathol; 2001 Jul; 159(1):119-30. PubMed ID: 11438460
[TBL] [Abstract][Full Text] [Related]
4. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.
de Paulsen N; Brychzy A; Fournier MC; Klausner RD; Gnarra JR; Pause A; Lee S
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1387-92. PubMed ID: 11171960
[TBL] [Abstract][Full Text] [Related]
5. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma.
McRonald FE; Morris MR; Gentle D; Winchester L; Baban D; Ragoussis J; Clarke NW; Brown MD; Kishida T; Yao M; Latif F; Maher ER
Mol Cancer; 2009 Jun; 8():31. PubMed ID: 19493342
[TBL] [Abstract][Full Text] [Related]
6. Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.
Schraml P; Hergovich A; Hatz F; Amin MB; Lim SD; Krek W; Mihatsch MJ; Moch H
Am J Pathol; 2003 Sep; 163(3):1013-20. PubMed ID: 12937142
[TBL] [Abstract][Full Text] [Related]
7. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
[TBL] [Abstract][Full Text] [Related]
8. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
9. Investigation of recurrent deletion loci specific to conventional renal cell carcinoma by comparative allelotyping in major epithelial carcinomas.
Bhat Singh RR; Amare Kadam PS
Indian J Urol; 2012 Jan; 28(1):47-52. PubMed ID: 22557717
[TBL] [Abstract][Full Text] [Related]
10. Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
Batavia AA; Rutishauser D; Sobottka B; Schraml P; Beerenwinkel N; Moch H
Mod Pathol; 2023 Aug; 36(8):100194. PubMed ID: 37088333
[TBL] [Abstract][Full Text] [Related]
11. A mutation at IVS1 + 5 of the von Hippel-Lindau gene resulting in intron retention in transcripts is not pathogenic in a patient with a tongue cancer?: case report.
Asakawa T; Esumi M; Endo S; Kida A; Ikeda M
BMC Med Genet; 2012 Mar; 13():23. PubMed ID: 22462637
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.
van Houwelingen KP; van Dijk BA; Hulsbergen-van de Kaa CA; Schouten LJ; Gorissen HJ; Schalken JA; van den Brandt PA; Oosterwijk E
BMC Cancer; 2005 Jun; 5():57. PubMed ID: 15932632
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells.
Harten SK; Esteban MA; Shukla D; Ashcroft M; Maxwell PH
Mol Cancer; 2011 Jul; 10():89. PubMed ID: 21791076
[TBL] [Abstract][Full Text] [Related]
14. Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated ccRCC.
Li L; Bao H; Xu Y; Yang W; Zhang Z; Ma K; Zhang K; Zhou J; Gong Y; Ci W; Gong K
Mol Diagn Ther; 2023 Nov; 27(6):741-752. PubMed ID: 37587253
[TBL] [Abstract][Full Text] [Related]
15. Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma.
Ricketts CJ; Morris MR; Gentle D; Shuib S; Brown M; Clarke N; Wei W; Nathan P; Latif F; Maher ER
Clin Epigenetics; 2013 Sep; 5(1):16. PubMed ID: 24034811
[TBL] [Abstract][Full Text] [Related]
16. Cloning of the rat homologue of the von Hippel-Lindau tumor suppressor gene and its non-somatic mutation in rat renal cell carcinomas.
Kikuchi Y; Kobayashi E; Nishizawa M; Hamazaki S; Okada S; Hino O
Jpn J Cancer Res; 1995 Oct; 86(10):905-9. PubMed ID: 7493907
[TBL] [Abstract][Full Text] [Related]
17. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.
Fisher R; Horswell S; Rowan A; Salm MP; de Bruin EC; Gulati S; McGranahan N; Stares M; Gerlinger M; Varela I; Crockford A; Favero F; Quidville V; André F; Navas C; Grönroos E; Nicol D; Hazell S; Hrouda D; O'Brien T; Matthews N; Phillimore B; Begum S; Rabinowitz A; Biggs J; Bates PA; McDonald NQ; Stamp G; Spencer-Dene B; Hsieh JJ; Xu J; Pickering L; Gore M; Larkin J; Swanton C
Genome Biol; 2014 Aug; 15(8):433. PubMed ID: 25159823
[TBL] [Abstract][Full Text] [Related]
18. von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations.
Tekin B; Erickson LA; Gupta S
Semin Diagn Pathol; 2024 Jan; 41(1):20-27. PubMed ID: 37980175
[TBL] [Abstract][Full Text] [Related]
19. Hereditary Renal Cancer Syndromes.
Yanus GA; Kuligina ES; Imyanitov EN
Med Sci (Basel); 2024 Feb; 12(1):. PubMed ID: 38390862
[TBL] [Abstract][Full Text] [Related]
20. Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma.
Kinoshita H; Yamada H; Ogawa O; Kakehi Y; Osaka M; Nakamura E; Mishina M; Habuchi T; Takahashi R; Sugiyama T
Jpn J Cancer Res; 1995 Sep; 86(9):795-9. PubMed ID: 7591954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
